NASDAQ:MGNX

MacroGenics Stock Forecast, Price & News

$21.33
-0.57 (-2.60 %)
(As of 06/11/2021 12:00 AM ET)
Add
Compare
Today's Range
$21.21
$22.00
50-Day Range
$21.33
$35.63
52-Week Range
$18.16
$36.48
Volume793,233 shs
Average Volume784,494 shs
Market Capitalization$1.28 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.28
30 days | 90 days | 365 days | Advanced Chart
Receive MGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for MacroGenics and its competitors with MarketBeat's FREE daily newsletter.


MacroGenics logo

About MacroGenics

MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics to treat cancer in the United States. The company's approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase II/III clinical trial for the treatment of breast and gastroesophageal cancers. The company is also developing Flotetuzumab, a DART molecule that recognizes CD123 and CD3 for treating acute myeloid leukemia; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; Enoblituzumab, a monoclonal antibody that targets B7-H3; and Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3. In addition, it is developing MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; MGD019, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company's non-immuno-oncology clinical product candidates include MGD014, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B Ã CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; Janssen Biotech, Inc.; and Alligator Bioscience AB (publ). The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.48 out of 5 stars

Medical Sector

615th out of 2,096 stocks

Pharmaceutical Preparations Industry

300th out of 830 stocks

Analyst Opinion: 3.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











MacroGenics (NASDAQ:MGNX) Frequently Asked Questions

Is MacroGenics a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last year. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MacroGenics stock.
View analyst ratings for MacroGenics
or view top-rated stocks.

What stocks does MarketBeat like better than MacroGenics?

Wall Street analysts have given MacroGenics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but MacroGenics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting MacroGenics?

MacroGenics saw a increase in short interest in the month of May. As of May 14th, there was short interest totaling 4,710,000 shares, an increase of 24.3% from the April 29th total of 3,790,000 shares. Based on an average daily trading volume, of 805,800 shares, the short-interest ratio is currently 5.8 days.
View MacroGenics' Short Interest
.

When is MacroGenics' next earnings date?

MacroGenics is scheduled to release its next quarterly earnings announcement on Thursday, July 29th 2021.
View our earnings forecast for MacroGenics
.

How were MacroGenics' earnings last quarter?

MacroGenics, Inc. (NASDAQ:MGNX) posted its earnings results on Thursday, April, 29th. The biopharmaceutical company reported ($0.90) earnings per share for the quarter, missing analysts' consensus estimates of ($0.53) by $0.37. The biopharmaceutical company had revenue of $16.88 million for the quarter, compared to analyst estimates of $31.16 million. MacroGenics had a negative net margin of 126.15% and a negative trailing twelve-month return on equity of 45.99%.
View MacroGenics' earnings history
.

How has MacroGenics' stock been impacted by COVID-19 (Coronavirus)?

MacroGenics' stock was trading at $6.49 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, MGNX stock has increased by 228.7% and is now trading at $21.33.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for MGNX?

6 Wall Street analysts have issued 1-year target prices for MacroGenics' stock. Their forecasts range from $17.00 to $41.00. On average, they anticipate MacroGenics' stock price to reach $33.00 in the next twelve months. This suggests a possible upside of 54.7% from the stock's current price.
View analysts' price targets for MacroGenics
or view top-rated stocks among Wall Street analysts.

Who are MacroGenics' key executives?

MacroGenics' management team includes the following people:
  • Dr. Scott Koenig, CEO, Pres & Director (Age 69, Pay $1.05M)
  • Mr. James Karrels, Sr. VP, CFO & Corp. Sec. (Age 54, Pay $613.84k)
  • Dr. Ezio Bonvini, Sr. VP of Research & Chief Scientific Officer (Age 67, Pay $658.21k)
  • Mr. Eric Blasius Risser, Sr. VP of Bus. Devel. & Portfolio Management and Chief Bus. Officer (Age 48, Pay $609.91k)
  • Dr. Stephen L. Eck, Sr. VP of Clinical Devel. & Chief Medical Officer (Age 66, Pay $577.62k)
  • Anna Krassowska Ph.D., VP of Investor Relations & Corp. Communications
  • Mr. Jeffrey Stuart Peters, VP & Gen. Counsel (Age 50)
  • Dr. Thomas M. Spitznagel, Sr. VP of BioPharmaceutical Devel. & Manufacturing (Age 54)
  • Ms. Lynn Cilinski, VP, Controller & Treasurer (Age 63)

What is Scott Koenig's approval rating as MacroGenics' CEO?

12 employees have rated MacroGenics CEO Scott Koenig on Glassdoor.com. Scott Koenig has an approval rating of 89% among MacroGenics' employees.

Who are some of MacroGenics' key competitors?

What other stocks do shareholders of MacroGenics own?

What is MacroGenics' stock symbol?

MacroGenics trades on the NASDAQ under the ticker symbol "MGNX."

Who are MacroGenics' major shareholders?

MacroGenics' stock is owned by many different retail and institutional investors. Top institutional investors include Bellevue Group AG (10.04%), BlackRock Inc. (9.63%), RA Capital Management L.P. (8.22%), Wasatch Advisors Inc. (6.83%), Perceptive Advisors LLC (3.58%) and RTW Investments LP (3.36%). Company insiders that own MacroGenics stock include Eric Blasius Risser, Ezio Bonvini, James Karrels, Jeffrey Stuart Peters, Kenneth Galbraith and Thomas Spitznagel.
View institutional ownership trends for MacroGenics
.

Which major investors are selling MacroGenics stock?

MGNX stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Nuveen Asset Management LLC, D. E. Shaw & Co. Inc., Millennium Management LLC, Arrowstreet Capital Limited Partnership, Tudor Investment Corp Et Al, Dimensional Fund Advisors LP, and Atom Investors LP. Company insiders that have sold MacroGenics company stock in the last year include Eric Blasius Risser, Ezio Bonvini, James Karrels, Jeffrey Stuart Peters, Kenneth Galbraith, and Thomas Spitznagel.
View insider buying and selling activity for MacroGenics
or view top insider-selling stocks.

Which major investors are buying MacroGenics stock?

MGNX stock was purchased by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Perceptive Advisors LLC, RTW Investments LP, BlackRock Inc., RA Capital Management L.P., Wasatch Advisors Inc., Opaleye Management Inc., and Darwin Global Management Ltd..
View insider buying and selling activity for MacroGenics
or or view top insider-buying stocks.

How do I buy shares of MacroGenics?

Shares of MGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MacroGenics' stock price today?

One share of MGNX stock can currently be purchased for approximately $21.33.

How much money does MacroGenics make?

MacroGenics has a market capitalization of $1.28 billion and generates $104.88 million in revenue each year. The biopharmaceutical company earns $-129,740,000.00 in net income (profit) each year or ($2.47) on an earnings per share basis.

How many employees does MacroGenics have?

MacroGenics employs 370 workers across the globe.

What is MacroGenics' official website?

The official website for MacroGenics is www.macrogenics.com.

Where are MacroGenics' headquarters?

MacroGenics is headquartered at 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850.

How can I contact MacroGenics?

MacroGenics' mailing address is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. The biopharmaceutical company can be reached via phone at 301-251-5172.


This page was last updated on 6/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.